Lalhmingmawii Qezvarthi · Chief Data Officer · India
Examine the product promise without taking over the survey
My contribution to a board
I could help a board ask what a data product has actually established before the enterprise makes a commercial commitment from it. My own freshness approval confused a recently edited record with a newly observed road. Later decisions concerned false network connections, expected restriction dates, limited redistribution rights and location points that did not identify the entrance the customer needed. These are different issues, but each shows how a complete-looking dataset can support a broader inference than its evidence allows. I would ask management to explain the intended decision, the source basis and the unresolved part of the offer. I would also ask whether a proposed programme funds new observation, better interpretation or simply a clearer account of existing evidence. The board should understand those differences when assessing the investment and the claim made afterward. My contribution would complement survey, commercial, financial and legal expertise. It would not turn a director into a route approver, a licensing lawyer or the person instructing analysts on each record.
Judgement in practice
01
Distinguishing a maintained release from renewed field evidence
The 120-segment freshness account contained fifty-six recent observations and sixty-four older observations with recent edits. I approved the broader description and then supported its correction. In a board discussion I would ask which event the reported date represents and whether management's claim exceeds it. The ₹41 lakh programme improved provenance; it did not establish that every segment had been visited again or that the physical network had improved. Directors could examine why the original approval failed and how the product now makes its evidence age intelligible. They would not need to set one expiry period for every road attribute. The useful oversight question is whether the enterprise has matched its offer to the evidence required for the customer's intended use.
02
Keeping commercial permission inside the product decision
Eighty-four of 120 selected source items permitted redistribution under the reviewed terms, while thirty-six were for internal research only. I supported a narrower release and ₹35 lakh of product and provenance work. A board could ask whether management's coverage promise assumes rights it has not established, who interprets the actual terms and what alternatives are available. It should not assume that a format change creates permission or that the restricted sources have no legitimate internal value. The decision may be to negotiate, narrow the offer or fund different evidence. Directors need that commercial choice and its cost, while the individual rights analysis remains with the qualified people authorised to make it.
My first year on a board
I would start by learning how the enterprise acquires evidence, turns it into an offer and maintains the meaning of that offer over time. Through access agreed with the chair, I would follow selected products from source to customer use and listen to the people responsible for field work, licensing, release and support. I would want to understand where a technical status becomes a commercial promise and how unresolved evidence reaches directors. I would not assume that Tavqelni's processes suit a different data business. The first task is to learn its actual responsibilities and the consequences of an incorrect inference for its customers. I would also examine how management distinguishes an enabling data repair from a measured operating benefit in investment reports. Nineteen days is a provisional capacity estimate, not a promise that every role can fit within it. Induction, preparation and urgent issues would need to be discussed with the chair and my employer. A useful first year would improve the questions I can contribute to collective oversight before I propose changes to a company I do not yet understand.
Conflicts and their management
A prospective company might buy our planning data, supply licensed sources, compete for survey assignments or share a relationship with Tavqelni's investors. I would disclose the relevant connections and discuss whether recusal, access restrictions or declining the opportunity were necessary. I would not bring restricted source files, unpublished survey observations, customer plans or confidential licence terms into another company's boardroom. The lesson from a data decision can inform my judgement without transferring the underlying material. Capacity also needs an honest account: a disputed release or urgent source question in my executive role could coincide with a board's immediate demand. That possibility belongs in the discussion before acceptance, particularly when the prospective enterprise relies on maintained products rather than isolated projects. I would revisit the arrangements when products, clients or ownership relationships changed, rather than assume an initial declaration settled every later conflict.
My independence statement
I am a Tavqelni employee without a personal or beneficial allocation in its ownership vehicle. For a proposed board role, I would identify relevant connections through the company, its investors, clients, source providers and survey partners. The absence of personal shares would not resolve independence. The actual relationships and applicable requirements would need current examination through the prospective company's proper process, with qualified advice where appropriate. I would keep that account under review as the source relationships and commercial responsibilities changed.
Board and committee exposure
Presented to the Board or a committee
Tavqelni Route Survey Services
Executive presentations on survey-data evidence, product scope and programme commitments
2017–present
Presented the freshness correction, network review, restriction-status work and source-rights release. This is executive exposure and does not constitute statutory company service.